Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19
Study Type/Phase: Expanded Access Program
The purpose of this study is to provide access to investigational convalescent plasma for patients who have severe or life-threatening COVID-19, or who are at high risk of progression to severe or life-threatening disease. Currently, there are no approved medications or vaccines to treat or prevent COVID-19, a disease caused by a virus called SARS-CoV-2 that was identified in late 2019. COVID-19 has been associated with cough, fever, shortness of breath, and in more severe cases, failure of the ability to breathe, or even death. People may recover from COVID-19 because their blood contains substances called antibodies, which are capable of fighting the virus that causes the illness. For some other diseases caused by respiratory viruses, giving people the liquid portion of blood, called plasma, obtained from those who have recovered from the virus, leads to more rapid improvement of the disease. Patients with COVID-19 may improve faster if they receive plasma from those who have recovered from COVID-19, because it may have the ability to fight the virus that causes COVID-19.
Speak with your doctor to determine whether you meet the following criteria for participation in this study.
For more information about this clinical trial, including trial status, eligibility and full trial listing, visit www.clinicaltrials.gov.